Patterns of Pharmacological Treatment for Osteoporosis Among Patients Qualified for Pharmacotherapy According to the National Osteoporosis Foundation Guidelines

Wang, Chi‐Chuan; Wu, Chung Hsuen; Farley, Joel F.

doi:10.1177/1060028015588127

Cited by 5 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found low rates of osteoporosis medication use in both men and women diagnosed with osteoporosis, but it was especially low among men. Osteoporosis medication use rates were found to be 44.3–42% in women and 25.2–24.5% in men in this study, which were on the higher end compared to what was found in the literature . Even after adjusting for age and other characteristics, the probability of an elderly man with diagnosed osteoporosis being treated with evidence‐based pharmacotherapy was just 20% of that in women.…”

Section: Discussioncontrasting

confidence: 73%

“…Men are not only less likely to be diagnosed with osteoporosis than women, and men are also treated less often than women even when diagnosed with osteoporosis. The prevalence of osteoporosis medication use ranges from 7.1 to 27% in men compared to 4.6 to 50% in women despite the fact that osteoporosis treatment guidelines recommend initiation of pharmacologic therapy in both men and women who have bone mineral density (BMD) T‐scores ≤−2.5 at the femoral neck or spine by dual‐energy x‐ray absorptiometry (DXA) and those who have experienced fragility fractures . The lower medication use rate in men may be owing to the lack of awareness of osteoporosis and its consequences in men .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differences in evidence‐based osteoporosis medication use between elderly men and women enrolled in Medicare Part D

Loh

Stuart

Davidoff³

et al. 2019

J Pharm Health Serv Res

View full text Add to dashboard Cite

Objective To compare osteoporosis treatment utilization rate between elderly men and women. Methods Cross‐sectional and panel analyses of Medicare beneficiaries (1) aged 70 years and older, (2) enrolled in Part A, B and Part D stand‐alone prescription drug plans from 1 January 2006 through 31 December 2008, or death, and (3) diagnosed of osteoporosis drawn from a random 5% sample of the Medicare population. Prescription drugs used to treat osteoporosis included bisphosphonates, calcitonin, parathyroid hormone analog and selective estrogen receptor modulator. Covariates included demographic characteristics, conditions and medications contributing to osteoporosis, bone fracture, or falls, contraindication and side effects of osteoporosis medications captured from Medicare claims. Key findings The study sample comprised 8465 men and 90 956 women with osteoporosis. Prevalence of osteoporosis medication use in men was substantially less than for women (25.2% versus 44.3% in 2006). With advancing age, men were more likely to be treated than women. Black men and women were much less likely (RR 0.76, 95% CI (0.68, 0.85) for men; RR 0.61, 95% CI (0.59, 0.63) for women) to be treated for osteoporosis compared to white men and women. Men who received BMD testing were much more likely to be treated compared to women. Bisphosphonates were the treatment of choice for both men and women, with nonbisphosphonate use increasing with advancing age. Conclusion Elderly men are significantly undertreated for osteoporosis compared to elderly women, and this is particularly problematic among blacks.

show abstract

Section: Discussioncontrasting

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Differences in evidence‐based osteoporosis medication use between elderly men and women enrolled in Medicare Part D

Loh

Stuart

Davidoff³

et al. 2019

J Pharm Health Serv Res

View full text Add to dashboard Cite

show abstract

“…1,2 Current prevention methods focus on patient education, exercise programs, and antiresorptive pharmacotherapy. 3,4 Cement reinforcement of the femoral neck has also been suggested as prevention for osteoporotic fractures. 5,6 Despite the benefits of these prevention methods, they are associated with many disadvantages, which highlight the need for further treatment options.…”

Section: Introductionmentioning

confidence: 99%

Local implantation of autologous adipose-derived stem cells increases femoral strength and bone density in osteoporotic rats: A randomized controlled animal study

Uri¹,

Behrbalk²,

Folman

2018

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

Background: Deficient osteogenic capacity of bone marrow stem cells plays a critical role in the pathophysiology of osteoporosis. Adipose-derived stem cells (ADSCs) have emerged as a promising source of skeletal progenitor cells. The capacity of ADSCs to undergo osteogenic differentiation and induce mineralized tissue formation may be beneficial in the treatment of osteoporosis. We question whether administration of autologous ADSCs into the proximal femur of osteoporotic rats will induce osteogenesis and enhance bone quality and strength. Materials and Methods: Thirty ovariectomized female rats were randomly assigned to one of the two treatment groups: (1) percutanous implantation of autogenous ADSCs-seeded scaffold into the proximal femur and (2) percutanous implantation of non-seeded scaffold. The contralateral untreated femur served as control. The effect of treatment on bone characteristics was assessed at 12-week follow-up by micro-computed tomography analysis, mechanical testing, and histological analysis. Results: The mean cortical thickness, total bone volume density, and bone load to failure in femora injected with autologous ADSCs-seeded scaffold was significantly higher compared to femora injected with non-seeded scaffold and compared to the untreated control femora (p < 0.01). Histological examination of the injected specimens revealed complete osseo-integration of the scaffolds with direct conversion of the ADSCs into osteoblasts and no inflammatory response. Conclusions: Autogenous ADSCs implantation into the proximal femur of rats with ovariectomy-related osteoporosis promoted bone regeneration and increased bone strength at short-term follow-up. These findings highlight the potential benefit of autogenous ADSCs in the treatment of osteoporosis. Level of Evidence: Level I, randomized controlled trial, animal study.

show abstract

“…Besides, men suffer from greater morbidity and mortality post-fracture compared to women [5,6]. They are also less likely to receive osteoporosis treatment compared women after a bone fracture [7].…”

Section: Introductionmentioning

confidence: 99%

The Role of Tocotrienol in Preventing Male Osteoporosis—A Review of Current Evidence

Chin

Ima‐Nirwana

2019

IJMS

View full text Add to dashboard Cite

Male osteoporosis is a significant but undetermined healthcare problem. Men suffer from a higher mortality rate post-fracture than women and they are marginalized in osteoporosis treatment. The current prophylactic agents for osteoporosis are limited. Functional food components such as tocotrienol may be an alternative option for osteoporosis prevention in men. This paper aims to review the current evidence regarding the skeletal effects of tocotrienol in animal models of male osteoporosis and its potential antiosteoporotic mechanism. The efficacy of tocotrienol of various sources (single isoform, palm and annatto vitamin E mixture) had been tested in animal models of bone loss induced by testosterone deficiency (orchidectomy and buserelin), metabolic syndrome, nicotine, alcoholism, and glucocorticoid. The treated animals showed improvements ranging from bone microstructural indices, histomorphometric indices, calcium content, and mechanical strength. The bone-sparing effects of tocotrienol may be exerted through its antioxidant, anti-inflammatory, and mevalonate-suppressive pathways. However, information pertaining to its mechanism of actions is superficial and warrants further studies. As a conclusion, tocotrienol could serve as a functional food component to prevent male osteoporosis, but its application requires validation from a clinical trial in men.

show abstract

Patterns of Pharmacological Treatment for Osteoporosis Among Patients Qualified for Pharmacotherapy According to the National Osteoporosis Foundation Guidelines

Abstract: Less than one-fourth of the population who should be considered for pharmacotherapy received osteoporosis treatment. Clinicians should be more aware of the unmet need for medication treatment for osteoporosis.

Cited by 5 publications

References 26 publications

Differences in evidence‐based osteoporosis medication use between elderly men and women enrolled in Medicare Part D

Differences in evidence‐based osteoporosis medication use between elderly men and women enrolled in Medicare Part D

Local implantation of autologous adipose-derived stem cells increases femoral strength and bone density in osteoporotic rats: A randomized controlled animal study

The Role of Tocotrienol in Preventing Male Osteoporosis—A Review of Current Evidence

Contact Info

Product

Resources

About